Application of MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis

Abstract

The invention relates to the technical field of an MAPK signal pathway inhibitor, in particular to application of the MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis. The invention discloses for the first time the application of the MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis, and further discloses for the first time application of Sorafenib Tosylate Tablets, U0126 or PD184352 in the MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis. Pharmacodynamic experimental data show that the treating effect of Sorafenib Tosylate Tablets, U0126 or PD184352 on cystic echinococcosis is superior or equivalent to that of clinically commonly used albendazole on cystic echinococcosis, that is, the MAPK signal pathway inhibitor can serve as a novel anti-echinococcosis drug for cystic echinococcosis, especially Sorafenib Tosylate Tablets, U0126 or PD184352, which can serve as a novel anti-echinococcosis drug, so that a novel approach is provided for cystic echinococcosis treatment.

Description

technical field [0001] The invention relates to the application technical field of MAPK signaling pathway inhibitors, and relates to the application of a MAPK signaling pathway inhibitor as a medicine for treating cystic echinococcosis. Background technique [0002] Echinococcosis, which is distributed worldwide, is also known as echinococcosis. Its larvae parasitize the human body and will cause serious zoonotic diseases. There are currently four recognized species, namely, E. granulosus (E.g), E. oligarthtus (E.o), E. multilocularis (E.m) and E. Echinococcus fowleri (E.vogeli, E.v), however, 95% of the cases are cystic echinococcosis (CystisEchinococccosis, CE) caused by Echinococcus granulosus (E.g) infection. Inner Mongolia, Sichuan, Gansu, Ningxia, Xinjiang, Qinghai and other seven provinces are high-incidence areas. The threatened population has reached 66 million, and the annual economic loss has exceeded 3 billion yuan. In 2006, China included it in the health plan...

AI Technical Summary

Problems solved by technology

However, the MAPK signaling pathway inhibitors Sorafenib, U0126 and PD184352 with anti-tumor effects have not been reported, and they can be applied to the treatment of cystic echinococcosis

Images